精神病学合作研究和许可协议（2019-2026）

本报告分析了 602 项精神病学领域的合作研究和许可协议，清楚地、以证据为基础地展示了整个市场伙伴关係的设计、协商和执行情况。

目录

执行摘要

第一章：引言

第二章：精神病学合约的趋势

• 介绍
• 过去几年精神医学合作
• 精神科合作：依合约类型划分
• 精神科合作：按产业划分
• 精神医学协作：依发展阶段
• 精神科协作：依技术类型划分
• 精神科协作：依疾病分类的治疗适应症

第三章 精神科合作的财务合约条款

• 介绍
• 精神科合作的公开财务条款与条件
• 精神科合作的主要金额
• 精神病学合约预付款
• 精神科合约的里程碑付款
• 精神科权利金费率

第四章：精神病学领域的主要合约和承包公司

• 介绍
• 在精神科合作领域最积极主动的公司
• 精神科领域最活跃的合约公司名单
• 按金额排名的顶级精神病学合同

第五章：精神科合约记录

• 介绍
• 可提供合约的精神科合作协议

第六章：精神医学的契约：依治疗目标划分

• 介绍
• 合约：按精神科治疗目标
• 合约记录
• 合约记录 - 精神病学合约：按公司分类（亚利桑那州）
• 合约记录 - 精神病学合约：按技术类型分类
• 合约类型的定义
• 关于 Biopharma Research Ltd.
• Current Partnering
• Current Agreements
• 理想合作伙伴近期报告标题

The definitive benchmark for psychiatry dealmaking

Psychiatry partnering spans a range of complex and high-risk CNS indications, with deal structures reflecting evolving approaches to clinical development, novel mechanisms of action, and significant unmet need.

This report provides a comprehensive and structured analysis of 602 psychiatry collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how psychiatry deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a high-risk and evolving therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within psychiatry partnerships, particularly in areas characterised by clinical uncertainty and complex development pathways.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 602 psychiatry collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for psychiatry dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how psychiatry partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in psychiatry dealmaking

• 2.1. Introduction
• 2.2. Psychiatry partnering over the years
• 2.3. Psychiatry partnering by deal type
• 2.4. Psychiatry partnering by industry sector
• 2.5. Psychiatry partnering by stage of development
• 2.6. Psychiatry partnering by technology type
• 2.7. Psychiatry partnering by therapeutic indication

Chapter 3 - Financial deal terms for psychiatry partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for psychiatry partnering
• 3.3. Psychiatry partnering headline values
• 3.4. Psychiatry deal upfront payments
• 3.5. Psychiatry deal milestone payments
• 3.6. Psychiatry royalty rates

Chapter 4 - Leading psychiatry deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in psychiatry partnering
• 4.3. List of most active dealmakers in psychiatry
• 4.4. Top psychiatry deals by value

Chapter 5 - Psychiatry contract document directory

• 5.1. Introduction
• 5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by psychiatry therapeutic target
• Deal directory
• Deal directory - Psychiatry deals by company A-Z
• Deal directory - Psychiatry deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Psychiatry partnering since 2019
• Figure 2: Psychiatry partnering by deal type since 2019
• Figure 3: Psychiatry partnering by industry sector since 2019
• Figure 4: Psychiatry partnering by stage of development since 2019
• Figure 5: Psychiatry partnering by technology type since 2019
• Figure 6: Psychiatry partnering by indication since 2019
• Figure 7: Psychiatry deals with a headline value
• Figure 8: Psychiatry deals with upfront payment values
• Figure 9: Psychiatry deals with milestone payment
• Figure 10: Psychiatry deals with royalty rates
• Figure 11: Active psychiatry dealmaking activity since 2019
• Figure 12: Top psychiatry deals by value since 2019